Researchers at Hiroshima University have identified a promising breast cancer therapeutic target involving vasoactive intestinal peptide receptor-2 (VIPR2) dimerization. Their study shows that dimeric VIPR2 promotes tumor growth and metastasis by enhancing downstream signals. Targeting the receptor’s transmembrane domain interactions could inhibit this dimerization, presenting a novel drug development pathway against breast cancer progression.